Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Death Dis ; 4: e581, 2013 Apr 04.
Article in English | MEDLINE | ID: mdl-23559015

ABSTRACT

Endoplasmic reticulum (ER) is the primary site for the synthesis and folding of secreted and membrane-bound proteins. Accumulation of unfolded and misfolded proteins in ER underlies a wide range of human neurodegenerative disorders. Hence, molecules regulating the ER stress response represent potential candidates as drug targets for tackling these diseases. Protein disulphide isomerase (PDI) is a chaperone involved in ER stress pathway, its activity being an important cellular defense against protein misfolding. Here, we demonstrate that human neuroblastoma SH-SY5Y cells overexpressing the reticulon protein 1-C (RTN1-C) reticulon family member show a PDI punctuate subcellular distribution identified as ER vesicles. This represents an event associated with a significant increase of PDI enzymatic activity. We provide evidence that the modulation of PDI localization and activity does not only rely upon ER stress induction or upregulation of its synthesis, but tightly correlates to an alteration in its nitrosylation status. By using different RTN1-C mutants, we demonstrate that the observed effects depend on RTN1-C N-terminal region and on the integrity of the microtubule network. Overall, our results indicate that RTN1-C induces PDI redistribution in ER vesicles, and concomitantly modulates its activity by decreasing the levels of its S-nitrosylated form. Thus RTN1-C represents a promising candidate to modulate PDI function.


Subject(s)
Endoplasmic Reticulum Stress/genetics , Endoplasmic Reticulum/metabolism , Nerve Tissue Proteins/genetics , Protein Disulfide-Isomerases/genetics , Transport Vesicles/metabolism , Cell Line, Tumor , Endoplasmic Reticulum/ultrastructure , Gene Expression Regulation , Humans , Microtubules/metabolism , Microtubules/ultrastructure , Mutation , Nerve Tissue Proteins/metabolism , Protein Disulfide-Isomerases/metabolism , Protein Folding , Protein Isoforms/genetics , Protein Isoforms/metabolism , Signal Transduction , Transport Vesicles/ultrastructure
2.
Oncogene ; 28(43): 3814-24, 2009 Oct 29.
Article in English | MEDLINE | ID: mdl-19668229

ABSTRACT

Reticulons are a family of highly conserved proteins, localized in the endoplasmic reticulum (ER) and involved in different cellular functions, such as intracellular membrane trafficking, apoptosis and nuclear envelope formation. The reticulon protein family consists of four members, but their specific functions are presently poorly understood. RTN-1C overexpression triggers apoptosis, regulating ER stress versus DNA damage-induced cell death in a mutually exclusive way. The different RTN isoforms share a C-terminal reticulon homology domain containing two hydrophobic segments and a 66-amino acid hydrophilic loop. In the C-terminal region of RTN-1C, a unique consensus sequence (GAKRH) has recently been identified, showing 100% identity with the DNA-binding domain of histone H4. In this study, we show that this sequence is essential for RTN-1C-mediated apoptosis. It is noteworthy that the lysine 204 present in this region is post-translationally modified by acetylation and that this event is associated with a significant decrease in histone deacetylase activity and contributes to RTN-1C binding to DNA. These data demonstrate a molecular mechanism by which RTN-1C controls apoptosis and indicate this protein to be a novel potential target for cancer therapy.


Subject(s)
Endoplasmic Reticulum/metabolism , Histone Deacetylase Inhibitors , Nerve Tissue Proteins/physiology , Neuroectodermal Tumors/metabolism , Acetylation , Apoptosis , Cell Line, Tumor , DNA/metabolism , Humans , Nerve Tissue Proteins/chemistry
3.
Cell Death Differ ; 15(2): 274-82, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18034188

ABSTRACT

Some chemotherapeutic agents can elicit apoptotic cancer cell death, thereby activating an anticancer immune response that influences therapeutic outcome. We previously reported that anthracyclins are particularly efficient in inducing immunogenic cell death, correlating with the pre-apoptotic exposure of calreticulin (CRT) on the plasma membrane surface of anthracyclin-treated tumor cells. Here, we investigated the role of cellular Ca(2+) homeostasis on CRT exposure. A neuroblastoma cell line (SH-SY5Y) failed to expose CRT in response to anthracyclin treatment. This defect in CRT exposure could be overcome by the overexpression of Reticulon-1C, a manipulation that led to a decrease in the Ca(2+) concentration within the endoplasmic reticulum lumen. The combination of Reticulon-1C expression and anthracyclin treatment yielded more pronounced endoplasmic reticulum Ca(2+) depletion than either of the two manipulations alone. Chelation of intracellular (and endoplasmic reticulum) Ca(2+), targeted expression of the ligand-binding domain of the IP(3) receptor and inhibition of the sarco-endoplasmic reticulum Ca(2+)-ATPase pump reduced endoplasmic reticulum Ca(2+) load and promoted pre-apoptotic CRT exposure on the cell surface, in SH-SY5Y and HeLa cells. These results provide evidence that endoplasmic reticulum Ca(2+) levels control the exposure of CRT.


Subject(s)
Anthracyclines/pharmacology , Calcium/metabolism , Calreticulin/metabolism , Cell Membrane/metabolism , Endoplasmic Reticulum/metabolism , Nerve Tissue Proteins/metabolism , Apoptosis , Brefeldin A/pharmacology , Cell Line, Tumor , HeLa Cells , Homeostasis , Humans , Protein Synthesis Inhibitors/pharmacology
5.
J Neurochem ; 75(2): 532-9, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10899928

ABSTRACT

Doxorubicin (0.5 microgram/ml) induced caspase-dependent apoptosis in SH-SY5Y neuroblastoma and CHP-100 neuroepithelioma cells. The apoptotic response started to be evident approximately 15 h after drug administration and, as monitored over a 48-h period, was more pronounced in CHP-100 than in SH-SY5Y cells. In both systems, apoptosis was accompanied by elevation of intracellular ceramide levels. Ceramide accumulation was blocked by the ceramide synthase inhibitor fumonisin B(1) (25 microM); this compound, however, did not prevent drug-induced apoptosis. Untreated cells from both lines expressed negligible p53 levels; on the other hand, whereas p53 and p21(Cip1/Waf1) were rapidly up-regulated in doxorubicin-treated SH-SY5Y cells, such a response was not observed in CHP-100 cells. Doxorubicin induced a G(2)/M phase block in both cell lines, but whereas the G(1) phase was markedly depleted in CHP-100 cells, it was substantially retained in SH-SY5Y cells. In the latter system, double G(1) and G(2)/M block largely preceded cell death; however, as apoptosis underwent completion, it selectively targeted late S and G(2)/M cells. Moreover, apoptosis suppression by caspase inhibition did not result in a recovery of the G(1) cell population. These results support the notion that doxorubicin-induced apoptosis and ceramide elevation are divorced events in neuroectodermal tumors and that p53 function is at least dispensable for apoptosis completion. Indeed, as G(1) cells appear to be refractory to doxorubicin-induced apoptosis, p53 up-regulation and p21(Cip1/Waf1) expression may provide an unfavorable setting for the apoptotic action of the drug.


Subject(s)
Apoptosis/physiology , Caspases/metabolism , Cell Cycle/physiology , Ceramides/metabolism , Doxorubicin/pharmacology , Amino Acid Chloromethyl Ketones/pharmacology , Apoptosis/drug effects , Brain Neoplasms , Caspase Inhibitors , Cell Cycle/drug effects , Enzyme Activation , G1 Phase , Humans , Kinetics , Neuroblastoma , Neuroectodermal Tumors, Primitive, Peripheral , Neuroprotective Agents/pharmacology , Tumor Cells, Cultured
6.
Cell Death Differ ; 6(7): 618-23, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10453072

ABSTRACT

The protein phosphatase inhibitor okadaic acid (OA) dose-dependently induced apoptosis in CHP-100 neuroepithelioma cells when administered for 24 h at concentrations ranging from 10 - 100 nM. Apoptosis was largely, albeit not completely, dependent on cystein protease (caspase) activation. CPP32 processing and poly(ADP-ribose) polymerase (PARP) cleavage started to be observed only at 20 nM OA; moreover, the caspase inhibitor Z-Val-Ala-DL-Asp-fluoromethylketone (Z-VAD.fmk) (100 microM) had negligible effect on apoptosis induced by 10 nM OA, but rescued from death an increasing cell fraction as OA concentration was raised from 20 - 100 nM. Cell treatment for 24 h with OA induced ceramide accumulation; the phenomenon started to be evident at 20 nM OA and reached its maximum at 50 - 100 nM OA. In cells exposed to 50 nM OA, ceramide was already elevated by 5 h; at this time, however, PARP cleavage and apoptosis were not yet observed. Z-VAD.fmk (100 microM) had no effect on ceramide elevation induced by 50 nM OA within 5 h, but markedly reduced ceramide accumulation as the incubation was prolonged to 24 h. The latter phenomenon was accompanied by elevation of glucosylceramide levels, thus suggesting that a caspase-dependent reduction of glucosylceramide synthesis might contribute to late ceramide accumulation. Short-chain ceramide (30 microM) induced apoptosis in CHP-100 cells and its effect was additive with that evoked by OA (10 - 20 nM). These results suggest that ceramide generation might be an important mechanism through which sustained protein phosphatase inhibition induces caspase activation and apoptosis in CHP-100 cells.


Subject(s)
Apoptosis/physiology , Caspases/metabolism , Ceramides/metabolism , Enzyme Inhibitors/pharmacology , Fumonisins , Okadaic Acid/pharmacology , Phosphoprotein Phosphatases/antagonists & inhibitors , Apoptosis/drug effects , Carboxylic Acids/pharmacology , Cell Death/drug effects , Enzyme Activation/drug effects , Enzyme Inhibitors/administration & dosage , Humans , Neuroectodermal Tumors, Primitive, Peripheral/drug therapy , Neuroectodermal Tumors, Primitive, Peripheral/metabolism , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Okadaic Acid/administration & dosage , Tumor Cells, Cultured
7.
Biochem Pharmacol ; 56(11): 1489-92, 1998 Dec 01.
Article in English | MEDLINE | ID: mdl-9827582

ABSTRACT

A major problem in assessing the role of calpains in apoptosis induction concerns the fact that calpain inhibitors can also impair the activity of the proteasome, also reported to be involved in apoptosis. Herein we showed that apoptosis induced by calphostin C in U937 human promonocytic leukemia cells was associated, at its onset, with enhanced protein (poly)ubiquitination. This observation prompted us to study whether protein degradation through the ubiquitin/proteasome pathway was involved in apoptosis induction. We found that N-acetyl-Leu-Leu-norleucinal (50 microM), a proteasome as well as a calpain inhibitor, was able to reduce calphostin C-induced apoptosis by approximately 60%, whereas lactacystin (10 microM), a specific proteasome inhibitor, was ineffective. These results suggest that calphostin C-induced apoptosis is partly calpain-mediated, but does not require protein degradation through the ubiquitin/proteasome pathway.


Subject(s)
Antibiotics, Antineoplastic/pharmacology , Apoptosis/drug effects , Calpain/metabolism , Naphthalenes/pharmacology , Acetylcysteine/analogs & derivatives , Acetylcysteine/pharmacology , Apoptosis/physiology , Calpain/antagonists & inhibitors , Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Humans , Leupeptins/pharmacology , Multienzyme Complexes/metabolism , Neoplasm Proteins/isolation & purification , Neoplasm Proteins/metabolism , Proteasome Endopeptidase Complex , Protein Processing, Post-Translational/drug effects , U937 Cells , Ubiquitins/metabolism
8.
Mol Cell Biol ; 17(10): 6040-8, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9315663

ABSTRACT

The retinoblastoma gene product (pRB) plays an important role in controlling both cell release from the G1 phase and apoptosis. We show here that in the early phases of apoptosis, pRB is posttranslationally modified by a tissue transglutaminase (tTG)-catalyzed reaction. In fact, by employing a novel haptenized lysis synthetic substrate which allows the isolation of glutaminyl-tTG substrates in vivo, we identified pRB as a potential tTG substrate in U937 cells undergoing apoptosis. In keeping with this finding, we showed that apoptosis of U937 cells is characterized by the rapid disappearance of the 105,000- to 110,000-molecular-weight pRB forms concomitantly with the appearance of a smear of immunoreactive products with a molecular weight of greater than 250,000. The shift in pRB molecular weight was reproduced by adding exogenous purified tTG to extracts obtained from viable U937 cells and was prevented by dansylcadaverine, a potent enzyme inhibitor. The effect of the pRB posttranslational modification during apoptosis was investigated by determining the E2F-1 levels and by isolating and characterizing pRB-null clones from U937 cells. Notably, the lack of pRB in these U937-derived clones renders these p53-null cells highly resistant to apoptosis induced by serum withdrawal, calphostin C, and ceramide. Taken together, these data suggest that tTG, acting on the pRB protein, might play an important role in the cell progression through the death program.


Subject(s)
Apoptosis/physiology , Carrier Proteins , Cell Cycle Proteins , DNA-Binding Proteins , GTP Phosphohydrolases/metabolism , GTP-Binding Proteins , Monocytes/metabolism , Protein Processing, Post-Translational/physiology , Retinoblastoma Protein/metabolism , Transglutaminases/metabolism , Apoptosis/drug effects , Blood , Cadaverine/analogs & derivatives , Cadaverine/pharmacology , Cell Line , Ceramides/pharmacology , E2F Transcription Factors , E2F1 Transcription Factor , Enzyme Inhibitors/pharmacology , GTP Phosphohydrolases/antagonists & inhibitors , Humans , Monocytes/cytology , Mutation , Naphthalenes/pharmacology , Phosphorylation , Protein Glutamine gamma Glutamyltransferase 2 , Protein Kinase C/antagonists & inhibitors , Proto-Oncogene Proteins c-bcl-2/analysis , Retinoblastoma Protein/genetics , Retinoblastoma-Binding Protein 1 , Transcription Factor DP1 , Transcription Factors/analysis , Transglutaminases/antagonists & inhibitors , Tretinoin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL